Exagen Inc. (XGN) News
Track canonical SquawkNews coverage tagged to XGN, Exagen Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Full Transcript: Exagen Q2 2026 Earnings Call
On Tuesday, Exagen (NASDAQ: XGN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts
LIVE | Sep 17, 2026, 11:19 AM UTC
L
XGN - Exagen Inc. Reports Second Quarter 2026 Financial Results
XGN - Exagen Inc. Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 12:01 PM UTC
L
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est
Exagen (NASDAQ: XGN ) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.
EARNINGS | Aug 04, 2026, 12:01 PM UTC
L
XGN - Exagen Inc. to Participate in Upcoming Investor Conference
XGN - Exagen Inc. to Participate in Upcoming Investor Conference
EQUITY | Jul 28, 2026, 01:00 PM UTC
M
XGN: Roth Initiates Buy
Roth Capital initiates coverage on Exagen with a Buy rating and $8 price target
EQUITY | Jun 25, 2026, 10:28 AM UTC